HOWL
Werewolf Therapeutics, Inc.·Healthcare
0.85
5.499%(−0.05)
Market ClosedLast Updated: — ET
52W L: $0.5352W H: $2.38
HOWL NEWS
globenewswire.com
Mar 27
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
globenewswire.com
Feb 24
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler & Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.
defenseworld.net
Feb 20
Analysts Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) PT at $3.75
Shares of Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) have earned a consensus recommendation of "Hold" from the seven research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the
defenseworld.net
Jan 14
Luke Evnin Sells 24,678 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 24,678 shares of the firm's stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $0.61, for a total value of $15,053.58. Following the completion of the sale, the director directly owned 2,368,849 shares
